AC-262

guinea pig

Also seen as: AC-262536, AC-262,536, AC262

The Dose Guy’s verdict

Sep 1, 2026
1 source

AC-262 has one rat pharmacology paper and a doping-detection study in horses. No human trial, no human pharmacokinetics, no safety profile beyond a rodent. If you want a SARM, ostarine has real clinical data. Running AC-262 is volunteering for an experiment nobody designed.

Would I take it?Not on one rat paper.

What it is

Acadia Pharmaceuticals screened this in the mid-2000s as part of the same partial-agonist SARM series that produced ACP-105. “Partial agonist” means it activates the androgen receptor more weakly than testosterone, enough to stimulate tissue but not enough to behave like a full androgen. One rat study tested that theory. No pharmaceutical company picked it up, no clinical program followed, and the only other published work is an equine metabolism study built for doping control.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

One pharmacology paper in rats and one doping-detection study in horses. The rat work is the only receipt that matters:

AC-262536 showed partial agonist activity at the androgen receptor and improved anabolic parameters in castrated male rats over two weeks, with weak androgenic effects on the prostate.J Steroid Biochem Mol Biol 2008 · cell + rat

No human clinical trial of AC-262 exists in the published literature.as of Aug 2026

Realistic protocols

I am not building a protocol out of one two-week rat study. Forum dosing runs 10 to 30 mg daily for six to eight weeks, but there is no human PK behind any of that. If you run it anyway: get a third-party COA on whatever you source, because a compound this obscure is an easy target for mislabeling. Suppression is the class rule, so have a PCT plan before you start. Bloodwork before and after, covering testosterone, lipids, and liver enzymes. Keep the cycle short and the dose low. Every SARM is WADA-prohibited if you compete.

Side effects

No human side-effect data exists. This is the SARM class profile and community reports:

anecdotalTestosterone suppression. The rat pharmacology paper documented LH suppression, so the mechanism is active, not just assumed from the class. Degree in a person is unknown.

anecdotalLipid shifts, particularly HDL drops, reported broadly across the SARM class.

unknownZero human safety data. No adverse events have been measured in a person, ever.

Where to buy

No live listings from tracked vendors right now.